CLINICAL AND LABORATORY INVESTIGATIONS
Timolol Maleate 0.5% or 0.1% Gel-Forming Solution for Infantile Hemangiomas: A Retrospective, Multicenter, Cohort Study
Article first published online: 9 DEC 2011
© 2011 Wiley Periodicals, Inc.
Volume 29, Issue 1, pages 28–31, January/February 2012
How to Cite
Chakkittakandiyil, A., Phillips, R., Frieden, I. J., Siegfried, E., Lara-Corrales, I., Lam, J., Bergmann, J., Bekhor, P., Poorsattar, S. and Pope, E. (2012), Timolol Maleate 0.5% or 0.1% Gel-Forming Solution for Infantile Hemangiomas: A Retrospective, Multicenter, Cohort Study. Pediatric Dermatology, 29: 28–31. doi: 10.1111/j.1525-1470.2011.01664.x
- Issue published online: 18 JAN 2012
- Article first published online: 9 DEC 2011
Abstract: Therapeutic options for superficial infantile hemangiomas (IH) are limited. Recently, timolol maleate gel, a topical nonselective beta-blocker, has been reported as a potentially effective treatment for superficial IH. This study is an extension of a previously published pilot study designed to further investigate the efficacy and safety and to identify predictors of good response of topical 0.5% or 0.1% timolol maleate gel-forming solution. This was a retrospective cohort study including patients enrolled from five centers. Patients were included if they were treated with timolol maleate 0.1% or 0.5% gel-forming solution and had photographic documentation of the IH and at least one follow-up visit. Patients with concomitant active treatment using other IH treatments were excluded. The primary endpoint was change in the appearance of IH as evaluated using a visual analog scale (VAS). Data from 73 subjects were available for final analysis. Timolol maleate gel-forming solution 0.5% was used in 85% (62/73) of patients, the remainder being treated with 0.1%. The median age at treatment initiation was 4.27 months (interquartile range [IQR] 2.63–7.21 mos), and patients were treated for a mean of 3.4 ± 2.7 months. All patients except one improved, with a mean improvement of 45 ± 29.5%. Predictors of better response were superficial type of hemangioma (p = 0.01), 0.5% timolol concentration (p = 0.01), and duration of use longer than 3 months (p = 0.04). Sleeping disturbance was noted in one patient. This study further demonstrates the efficacy and tolerability of topical timolol maleate and gradual improvement with longer treatment in patients with superficial IH.